Long-Term Outcomes in Patients with Locally Advanced and Metastatic Non-Small Cell Lung Cancer with High PD-L1 Expression

Long-Term Outcomes in Patients with Locally Advanced and Metastatic Non-Small Cell Lung Cancer with High PD-L1 Expression

Before the introduction of targeted therapy and immunotherapy, patients with metastatic non-small-cell lung cancer (NSCLC) had a 5-year overall survival (OS) rate of up to 10%. After the positive results of KEYNOTE-024, pembrolizumab was approved in a first-line setting for patients with metastatic...

Full description

Saved in:
Bibliographic Details
Main Authors: Vesna Ćeriman Krstić, Ivan Soldatović, Milija Gajić, Natalija Samardžić, Ruža Stević, Nikola Čolić, Katarina Lukić, Biljana Šeha, Damir Radončić, Slavko Stamenić, Milan Savić, Vladimir Milenković, Brankica Milošević Maračić, Dragana Jovanović
Format: Article
Language:English
Published: MDPI AG 2025-04-01
Series:Current Oncology
Subjects:
NSCLC
immunotherapy
pembrolizumab
long-term outcomes
PFS
OS
Online Access:https://www.mdpi.com/1718-7729/32/4/229
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items